MetLife Investment Management’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $204M | Sell |
221,464
-7,656
| -3% | -$7.76M | 1.04% | 11 |
|
|
2025
Q4 | $246M | Sell |
229,120
-6,180
| -3% | -$5.91M | 1.19% | 10 |
|
|
2025
Q3 | $180M | Sell |
235,300
-1,848
| -0.8% | -$1.38M | 0.86% | 13 |
|
|
2025
Q2 | $185M | Sell |
237,148
-2,600
| -1% | -$2.02M | 1.09% | 9 |
|
|
2025
Q1 | $198M | Sell |
239,748
-4,332
| -2% | -$3.6M | 1.07% | 12 |
|
|
2024
Q4 | $188M | Buy |
244,080
+2,280
| +0.9% | +$1.89M | 1.02% | 12 |
|
|
2024
Q3 | $214M | Sell |
241,800
-11,549
| -5% | -$10.4M | 1.23% | 11 |
|
|
2024
Q2 | $229M | Buy |
253,349
+30,675
| +14% | +$24.5M | 1.36% | 8 |
|
|
2024
Q1 | $173M | Sell |
222,674
-6,742
| -3% | -$4.8M | 1.16% | 11 |
|
|
2023
Q4 | $134M | Sell |
229,416
-4,066
| -2% | -$2.37M | 0.96% | 13 |
|
|
2023
Q3 | $125M | Sell |
233,482
-2,931
| -1% | -$1.51M | 0.98% | 13 |
|
|
2023
Q2 | $111M | Buy |
236,413
+4,370
| +2% | +$1.83M | 0.81% | 13 |
|
|
2023
Q1 | $79.7M | Sell |
232,043
-2,368
| -1% | -$799K | 0.57% | 22 |
|
|
2022
Q4 | $85.8M | Sell |
234,411
-4,526
| -2% | -$1.6M | 0.65% | 21 |
|
|
2022
Q3 | $77.3M | Sell |
238,937
-2,774
| -1% | -$879K | 0.64% | 20 |
|
|
2022
Q2 | $78.4M | Sell |
241,711
-5,391
| -2% | -$1.62M | 0.61% | 23 |
|
|
2022
Q1 | $70.8M | Buy |
247,102
+71,680
| +41% | +$18.4M | 0.46% | 29 |
|
|
2021
Q4 | $48.5M | Sell |
175,422
-3,903
| -2% | -$989K | 0.4% | 40 |
|
|
2021
Q3 | $41.4M | Sell |
179,325
-5,222
| -3% | -$1.29M | 0.37% | 49 |
|
|
2021
Q2 | $42.4M | Sell |
184,547
-5,018
| -3% | -$1.01M | 0.37% | 46 |
|
|
2021
Q1 | $35.4M | Sell |
189,565
-3,253
| -2% | -$636K | 0.32% | 53 |
|
|
2020
Q4 | $32.6M | Sell |
192,818
-8,463
| -4% | -$1.26M | 0.31% | 56 |
|
|
2020
Q3 | $29.8M | Sell |
201,281
-18,984
| -9% | -$2.94M | 0.33% | 56 |
|
|
2020
Q2 | $36.2M | Buy |
220,265
+2,477
| +1% | +$380K | 0.41% | 40 |
|
|
2020
Q1 | $30.2M | Sell |
217,788
-6,663
| -3% | -$915K | 0.41% | 44 |
|
|
2019
Q4 | $29.5M | Sell |
224,451
-6,751
| -3% | -$783K | 0.31% | 62 |
|
|
2019
Q3 | $25.9M | Sell |
231,202
-6,961
| -3% | -$775K | 0.28% | 65 |
|
|
2019
Q2 | $26.4M | Sell |
238,163
-7,372
| -3% | -$868K | 0.28% | 65 |
|
|
2019
Q1 | $31.9M | Sell |
245,535
-24,085
| -9% | -$2.93M | 0.35% | 54 |
|
|
2018
Q4 | $31.2M | Sell |
269,620
-8,439
| -3% | -$943K | 0.38% | 46 |
|
|
2018
Q3 | $29.8M | Sell |
278,059
-3,123
| -1% | -$312K | 0.31% | 60 |
|
|
2018
Q2 | $24M | Sell |
281,182
-8,961
| -3% | -$736K | 0.28% | 59 |
|
|
2018
Q1 | $22.4M | Sell |
290,143
-9,633
| -3% | -$775K | 0.26% | 67 |
|
|
2017
Q4 | $25.3M | Buy |
+299,776
| New | +$25.5M | 0.29% | 62 |
|
Other funds holding LLY
VCM
VPM
MetLife Investment Management's LLY Position: Q1 2026 in Review
MetLife Investment Management reduced its Eli Lilly (LLY) stake by 3.3% in Q1 2026, selling an estimated $7.76M and leaving 221,464 shares worth $204M. The position accounts for 1.04% of the portfolio, ranked #11.
MetLife Investment Management first reported a position in LLY in Q4 2017 and has held it in 34 quarters since. The position peaked at $246M in Q4 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.
- MetLife Investment Management held 221,464 shares of Eli Lilly worth $204M as of Q1 2026.
- MetLife Investment Management sold 7,656 Eli Lilly shares in Q1 2026, an estimated $7.76M.
- Eli Lilly made up 1.04% of MetLife Investment Management's portfolio in Q1 2026, its #11 holding.
- MetLife Investment Management first reported a position in Eli Lilly in Q4 2017 and has held it in 34 quarters since.
- MetLife Investment Management's Eli Lilly position peaked at $246M in Q4 2025.
- 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.
Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.